Return to study ST001908 main page

MB Sample ID: SA176825

Local Sample ID:P341
Subject ID:SU001986
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Human Inclusion Criteria:a. Clinically diagnosed ST-elevation myocardial infarction (STEMI) • Typical history of ischemic chest pain or angina equivalent symptoms (acute onset dyspnea) • ECG changes of at least 2 contiguous leads of ≥2 mm (0.2 mV) in men or ≥1.5 mm (0.15 mV) in women in leads V2–V3 and/or of ≥1 mm (0.1 mV) in other contiguous chest leads or the limb leads • Presence of Q waves • Typical rise and fall of cardiac enzymes (cTn value exceeding the 99th percentile URL (in ng/L or pg/mL) OR Clinically diagnosed nonST-elevation myocardial infarction (NSTEMI) • ECG changes of ST-segment depression or prominent T-wave inversion and/or • positive biomarkers of necrosis (troponin, CKMB) b. Angiographic findings of >50% occlusion of one or more coronary arteries c. Age>21 years and <85 years, d. Ability to provide written informed consent and comply with study protocol requirements.
Human Exclusion Criteria:a. Patients not able or willing to consent for study b. Severe renal impairment (eGFR<15 ml/min/m2) c. Severe liver impairment d. Anaemia < 8 g/dl (men) and 7 g/dl (women) e. Cardiogenic shock unable to be weaned off inotropes or IABP f. History of significant valvular heart disease (moderate or severe MS, MR, AS, AR, TR) g. History of malignancy diagnosed within the last 12 months h. Patients who cannot be followed up (non-residents)

Select appropriate tab below to view additional metadata details:

Subject:

Subject ID:SU001986
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Human Inclusion Criteria:a. Clinically diagnosed ST-elevation myocardial infarction (STEMI) • Typical history of ischemic chest pain or angina equivalent symptoms (acute onset dyspnea) • ECG changes of at least 2 contiguous leads of ≥2 mm (0.2 mV) in men or ≥1.5 mm (0.15 mV) in women in leads V2–V3 and/or of ≥1 mm (0.1 mV) in other contiguous chest leads or the limb leads • Presence of Q waves • Typical rise and fall of cardiac enzymes (cTn value exceeding the 99th percentile URL (in ng/L or pg/mL) OR Clinically diagnosed nonST-elevation myocardial infarction (NSTEMI) • ECG changes of ST-segment depression or prominent T-wave inversion and/or • positive biomarkers of necrosis (troponin, CKMB) b. Angiographic findings of >50% occlusion of one or more coronary arteries c. Age>21 years and <85 years, d. Ability to provide written informed consent and comply with study protocol requirements.
Human Exclusion Criteria:a. Patients not able or willing to consent for study b. Severe renal impairment (eGFR<15 ml/min/m2) c. Severe liver impairment d. Anaemia < 8 g/dl (men) and 7 g/dl (women) e. Cardiogenic shock unable to be weaned off inotropes or IABP f. History of significant valvular heart disease (moderate or severe MS, MR, AS, AR, TR) g. History of malignancy diagnosed within the last 12 months h. Patients who cannot be followed up (non-residents)

Factors:

Local Sample IDMB Sample IDFactor Level IDLevel ValueFactor Name
P341SA176825FL021921AMICondition
P341SA176825FL021921MalayRace
P341SA176825FL021921MaleGender
P341SA176825FL021921Former-smokerSmoker

Collection:

Collection ID:CO001979
Collection Summary:1. Collect blood into 2.7 ml citrated vacutainers. 2. Add Theophylline, adenosine and dipyridamole (TAD) solution into the citrated blood to final concentrations of 1.5mM, 0.37mM and 0.0198mM respectively. Mix gently by inverting for 4-6 times. 3. Centrifuge at 150g for 10min, RT 4. Collect PRP (leaving approx. 5mm) into a 5 ml polypropylene tube 5. Centrifuge again at 150g for 10min, RT 6. Collect PRP (leaving approx. 5mm) into the same tube from step 4 7. Add apyrase (final concentration: 0.04 U/mL) and 1 vol of 2.5X TAD-PBS 8. Mix gently by inverting tubes 5 times 9. Centrifuge diluted PRP at 100g for 10 min at RT 10. Transfer supernatant into a new 5 ml polypropylene tube 11. Centrifuge supernatant at 1000g for 10 min 12. Discard supernatant 13. Add 1.5mL of 2.5X TAD/PWD (1.5mM theophylline, 0.37mM adenosine and 0.0198mM dipyridamole in 140mM NaCl, 10mM NaHCO3, 2.5mM KCl, 0.5mM Na2HPO4, 1mM MgCl2, 6.46mM Na3C6H5O7 and 0.1% glucose, pH 6.5) containing apyrase (0.04 U/mL). 14. Gently resuspend and centrifuge at 1000g for 9 min using the tabletop Eppendorf centrifuge 15. Discard supernatant 16. Either keep the platelet pellet -80oC until analysis or resuspended in tyrode’s (134 mM NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1.0 mM MgCl2, 10 mM HEPES and 5 mM glucose, pH 7.4) buffers for flow cytometry analysis.
Sample Type:Platelets
Storage Conditions:-80℃

Treatment:

Treatment ID:TR001998
Treatment Summary:No treatment/intervention was done to the patients prior to sample collection for this project. Platelet samples were obtained from healthy volunteers and patients with coronary heart disease. Medication was given after diagnosis, but they are not included as variables in this project.

Sample Preparation:

Sampleprep ID:SP001992
Sampleprep Summary:Simultaneous extraction of metabolites and glycans.

Combined analysis:

Analysis ID AN003105
Analysis type MS
Chromatography type HILIC
Chromatography system Thermo Dionex Ultimate 3000
Column Waters XBridge Amide (100 x 2.1 mm,3.5um)
MS Type ESI
MS instrument type new
MS instrument name ABI Sciex 5500 QTrap
Ion Mode POSITIVE
Units a.u.

Chromatography:

Chromatography ID:CH002292
Instrument Name:Thermo Dionex Ultimate 3000
Column Name:Waters XBridge Amide (100 x 2.1 mm,3.5um)
Chromatography Type:HILIC

MS:

MS ID:MS002887
Analysis ID:AN003105
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:new
MS Type:ESI
MS Comments:Both Positive and negative modes were used
Ion Mode:POSITIVE
  logo